Document is current
Any future updates will be listed below
-
Authors
Okoli, Rosemary C. B.
Shedul, Gabriel
Hirschhorn, Lisa R.
Orji, Ikechukwu A.
Ojo, Tunde M.
Egenti, Nonye
Omitiran, Kasarachi
Akor, Blessing
Baldridge, Abigail S.
Huffman, Mark D.
Ojji, Dike
Kandula, Namratha R. http://orcid.org/0000-0003-2570-3426
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL144708)
- License Information
-
More Information
Article History
Received: 10 December 2020
Accepted: 5 August 2021
First Online: 30 August 2021
Declarations
:
: The study was reviewed and approved by the Ethics Committee at the University of Abuja and the Institutional Review Board at Northwestern University.
: At the start of the focus groups and interviews, participants provided written, informed consent. There are no personally identifying details, images, or videos included in this manuscript.
: In the past 3 years, MDH received funding from the World Heart Federation to serve as its senior program advisor for the Emerging Leaders program, which is supported by Boehringer Ingelheim and Novartis with previous support from BUPA and AstraZeneca. MDH also received support from the American Heart Association, Verily, and AstraZeneca and American Medical Association for work unrelated to this research. The George Institute for Global Health’s wholly owned enterprise, George Health Enterprises, has received investment funds to develop fixed-dose combination products containing aspirin, statin, and blood pressure lowering drugs. MDH plans to submit patents for heart failure polypills.
